Brown Advisory
IBER

Brown Advisory’s Ibere Pharmaceuticals IBER Stock Holding History

Brown Advisory’s Portfolio IBER Stock Details IBER Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-2,728,334
Closed -$11.1M – 1179
2022
Q2 		$11.1M Hold
2,728,334
– – 0.02% 370
2022
Q1 		$11.3M Hold
2,728,334
– – 0.02% 375
2021
Q4 		$11.7M Buy
+2,728,334
New +$26.5M 0.01% 381

Other funds holding IBER

GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
FTCM
First Trust Capital Management Chicago, Illinois $1.9B AUM 58.39% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
PC
Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return
KL
KIM LLC Wichita, Kansas $976M AUM 0.91% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return

Brown Advisory's IBER Position: Q3 2022 in Review

Brown Advisory sold out of Ibere Pharmaceuticals (IBER) in Q3 2022, closing a stake of 2,728,334 shares — an estimated $11.1M sold.

Brown Advisory first reported a position in IBER in Q4 2021 and held it in 3 quarters. The position peaked at $11.7M in Q4 2021. 48 funds tracked by Wall St. Rank hold IBER as of Q3 2022.

  • Brown Advisory reported no remaining Ibere Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
  • Brown Advisory sold 2,728,334 Ibere Pharmaceuticals shares in Q3 2022, an estimated $11.1M.
  • Brown Advisory first reported a position in Ibere Pharmaceuticals in Q4 2021 and held it in 3 quarters.
  • Brown Advisory's Ibere Pharmaceuticals position peaked at $11.7M in Q4 2021.
  • 48 funds tracked by Wall St. Rank held Ibere Pharmaceuticals as of Q3 2022.

Based on Brown Advisory's 13F filing for Q3 2022, filed 14 Nov 2022.